Kodiak Sciences Inc. (KOD)
About Kodiak Sciences Inc.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$230.0M
- Total assets
- $351.5M
- Market cap
- $1.9B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $234.4M
- Operating income
- -$234.4M
- Income tax
- $52.0K
- Net income
- -$230.0M
- EPS (basic)
- $-4.32
- EPS (diluted)
- $-4.32
Balance sheet
- Total assets
- $351.5M
- Current assets
- $214.8M
- Total liabilities
- $194.2M
- Current liabilities
- $45.5M
- Shareholders’ equity
- $157.4M
Cash flow
- Operating cash flow
- -$136.0M
- Investing cash flow
- -$506.0K
- Financing cash flow
- $178.3M
- Net cash flow
- $41.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-4.32
- Shares outstanding
- 46.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 4, 2018
Kodiak Sciences Inc. (KOD) Stock Price
- Reported a net loss of $230.0M.
- Trading 11% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kodiak Sciences Inc..
Write a review
News about Kodiak Sciences Inc.
News & sentiment via Polygon.io
Kodiak Sciences Inc.: frequently asked questions
Is Kodiak Sciences Inc. an American company?
Kodiak Sciences Inc. is a US-based company headquartered in Palo Alto, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Kodiak Sciences Inc. headquartered?
Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States.
Is Kodiak Sciences Inc. publicly traded?
Yes — Kodiak Sciences Inc. is a publicly traded company. Its stock trades under the ticker symbol KOD on the NASDAQ.
What does Kodiak Sciences Inc. do?
Kodiak Sciences Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
